hello world!
Published: September 6, 2023

Conference Co-Chair Spotlight - Seattle Cellular Therapy Summit 2023

Drs. Krish Patel and Mazyar Shadman performed as Conference Co-Chairs at the Cellular Therapy Summit 2023 in Seattle, WA

Drs. Krish Patel of Swedish First Hill Hospital and Mazyar Shadman of Fred Hutchinson Cancer Center co-chaired Binaytara Foundation's Seattle Cellular Therapy Summit on August 4 & 5, 2023. Dr. Patel and Dr. Shadman contributed to the successful planning and execution of this important oncology conference.

The goal of the conference was to strengthen the foundational knowledge and clinical expertise of healthcare providers in patient-centric cellular therapy. The achievement of this objective was made possible through the efforts of Dr. Krish Patel and Dr. Mazyar Shadman.

BTF is a non-profit organization dedicated to reducing cancer disparities through the implementation of education, advocacy, and innovation. Our mission is to provide cancer care practitioners with access to quality continuing education, regardless of their geographical location. We would like to express our gratitude to Dr. Krish Patel and Dr. Mazyar Shadman for contributing to our mission.

BTF's assistant communication coordinator Taylor Pak sat down with Drs. Patel and Shadman for brief interviews to share their experiences as the Seattle Cellular Therapy Summit conference co-chairs.


Dr. Krish Patel

Based in Seattle, WA, Dr. Patel is an oncologist who specializes in blood cancers with a particular interest in lymphoma research. He is currently affiliated with Swedish First Hill Hospital, where he is dedicated to developing novel therapies for blood-cancer patients through clinical trials. Dr. Patel received his medical degree from Duke University in Durham, North Carolina, and has been in practice for about fourteen years.

In the interview, Dr. Krish Patel describes his experience as conference co-chair of BTF's Seattle Cellular Therapy Summit and touches on co-chair responsibilities. Check out the video!


Dr. Mazyar Shadman

As an associate professor at Fred Hutch Cancer Center in Seattle, WA, Dr. Shadman shares the same field of expertise in blood cancer as Dr. Patel, with a particular emphasis on lymphoid malignancies and immunotherapies. He is an expert in stem-cell transplants and his clinical trial work maintains a heavy focus on the treatment of chronic lymphocytic leukemia (CLL). Dr. Shadman has been affiliated with Fred Hutch Cancer Center and the University of Washington for over 10 years.

In the interview, Dr. Mazyar Shadman describes his excitement to be a conference co-chair at the Seattle Cellular Therapy Summit. Watch the video to learn more!


About Binaytara Foundation

Binaytara Foundation (BTF) is an international global oncology non-profit organization dedicated to improving access to cancer care. Through education, advocacy, and innovations, BTF aims to improve access to cancer care for everyone around the world so that there are minimal to no disparities in cancer health outcomes.

Minimizing Cancer Disparities Through Education and Innovation
Binaytara Foundation is a leader in hematology and oncology continuing education. BTF's multi-channel approach to oncology continuing education includes oncology conferences, The Cancer News, The International Journal of Cancer Care & Delivery, and virtual enduring materials.

A Global Oncology Leader
Binaytara Foundation's global oncology programs include the establishment of a cancer hospital in Janakpurdham, Nepal. BTF's prior global oncology programs include supporting the development of the first bone marrow transplant center in Kathmandu, Nepal, and palliative care initiatives in South Asia.

Continuing Medical Education

BTF is a leading provider of CME-accredited courses and meetings, featuring leading experts in oncology and hematology education. For more information on these conferences, visit Binaytara Foundation's Education Academy website.

Please visit the organization's website to learn more about the Binaytara Foundation's impact missions.